Literature DB >> 30734249

Antagonistic effect between tigecycline and meropenem: successful management of KPC-producing Klebsiella pneumoniae infection.

Sheng Bi1, Xin Yao2, Cheng Huang1,3, Xia Zheng4, Tianming Xuan5, Jifang Sheng1, Kaijin Xu1, Beiwen Zheng6,7, Qing Yang8.   

Abstract

INTRODUCTION: A woman infected by carbapenem-resistant Klebsiella pneumoniae is reported in this study. CASE REPORT: Tigecycline and meropenem combination was used, and indeed, in vitro checkerboard synergy test confirmed the antagonism between the two antibiotics. Thus, meropenem was ceased and single high-dose tigecycline was successful against the infection. Subsequent experiments showed that the isolates of the KPC-2-producing K. pneumoniae ST11 clone caused the infection.
CONCLUSION: Therefore, tigecycline and meropenem combination should be used with caution.

Entities:  

Keywords:  Antagonistic effect; Carbapenem-resistance; KPC-2-producing Klebsiella pneumoniae; Meropenem; Tigecycline

Mesh：

Substances：

Year:  2019        PMID： 30734249     DOI： 10.1007/s15010-019-01274-w

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


  16 in total

1.  Antagonism between bacteriostatic and bactericidal antibiotics is prevalent.

Authors:  Paolo S Ocampo; Viktória Lázár; Balázs Papp; Markus Arnoldini; Pia Abel zur Wiesch; Róbert Busa-Fekete; Gergely Fekete; Csaba Pál; Martin Ackermann; Sebastian Bonhoeffer
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

2.  Therapy of 1,025 severely ill patients with complicated infections in a German multicenter study: safety profile and efficacy of tigecycline in different treatment modalities.

Authors:  Klaus-Friedrich Bodmann; Wolfgang R Heizmann; Christof von Eiff; Christian Petrik; Peter-Andreas Löschmann; Christian Eckmann
Journal:  Chemotherapy       Date:  2012-10-04       Impact factor: 2.544

3.  In vitro evaluation of antibiotic synergy for polymyxin B-resistant carbapenemase-producing Klebsiella pneumoniae.

Authors:  Azza Elemam; Joseph Rahimian; Mehmet Doymaz
Journal:  J Clin Microbiol       Date:  2010-08-04       Impact factor: 5.948

4.  Activity of antimicrobial combinations against KPC-2-producing Klebsiella pneumoniae in a rat model and time-kill assay.

Authors:  Paula Virginia Michelon Toledo; Ayrton Alves Aranha Junior; Lavinia Nery Arend; Vanessa Ribeiro; Alexandre Prehn Zavascki; Felipe Francisco Tuon
Journal:  Antimicrob Agents Chemother       Date:  2015-04-20       Impact factor: 5.191

5.  Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.

Authors:  Spyros Pournaras; Georgia Vrioni; Evangelia Neou; John Dendrinos; Evangelia Dimitroulia; Aggeliki Poulou; Athanassios Tsakris
Journal:  Int J Antimicrob Agents       Date:  2011-01-13       Impact factor: 5.283

6.  Laboratory diagnosis, clinical management and infection control of the infections caused by extensively drug-resistant Gram-negative bacilli: a Chinese consensus statement.

Authors:  X Guan; L He; B Hu; J Hu; X Huang; G Lai; Y Li; Y Liu; Y Ni; H Qiu; Z Shao; Y Shi; M Wang; R Wang; D Wu; C Xie; Y Xu; F Yang; K Yu; Y Yu; J Zhang; C Zhuo
Journal:  Clin Microbiol Infect       Date:  2015-11-25       Impact factor: 8.067

Review 7.  Carbapenemase-Producing Klebsiella pneumoniae, a Key Pathogen Set for Global Nosocomial Dominance.

Authors:  Johann D D Pitout; Patrice Nordmann; Laurent Poirel
Journal:  Antimicrob Agents Chemother       Date:  2015-07-13       Impact factor: 5.191

Review 8.  Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases.

Authors:  L Silvia Munoz-Price; Laurent Poirel; Robert A Bonomo; Mitchell J Schwaber; George L Daikos; Martin Cormican; Giuseppe Cornaglia; Javier Garau; Marek Gniadkowski; Mary K Hayden; Karthikeyan Kumarasamy; David M Livermore; Juan J Maya; Patrice Nordmann; Jean B Patel; David L Paterson; Johann Pitout; Maria Virginia Villegas; Hui Wang; Neil Woodford; John P Quinn
Journal:  Lancet Infect Dis       Date:  2013-09       Impact factor: 25.071

9.  Activity of Tigecycline in combination with Colistin, Meropenem, Rifampin, or Gentamicin against KPC-producing Enterobacteriaceae in a murine thigh infection model.

Authors:  George Michail; Maria Labrou; Vassiliki Pitiriga; Styliani Manousaka; Nikolaos Sakellaridis; Athanasios Tsakris; Spyros Pournaras
Journal:  Antimicrob Agents Chemother       Date:  2013-09-23       Impact factor: 5.191

10.  Efficacy of tigecycline, polymyxin, gentamicin, meropenem and associations in experimental Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae non-lethal sepsis.

Authors:  Paula Virginia Michelon Toledo; Felipe Francisco Tuon; Lavinia Arend; Ayrton Alves Aranha Junior
Journal:  Braz J Infect Dis       Date:  2014-06-05       Impact factor: 3.257
View more
  6 in total

1.  Comparative serum bactericidal activity of meropenem-based combination regimens against extended-spectrum beta-lactamase and KPC-producing Klebsiella pneumoniae.

Authors:  Paolo Gaibani; Donatella Lombardo; Michele Bartoletti; Simone Ambretti; Caterina Campoli; Maddalena Giannella; Sara Tedeschi; Matteo Conti; Rita Mancini; Maria Paola Landini; Maria Carla Re; Pierluigi Viale; Russell E Lewis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-07-06       Impact factor: 3.267

2.  In vitro and in vivo Effect of Antimicrobial Agent Combinations Against Carbapenem-Resistant Klebsiella pneumoniae with Different Resistance Mechanisms in China.

Authors:  Enbo Liu; Peiyao Jia; Xue Li; Menglan Zhou; Timothy Kudinha; Chuncai Wu; Yingchun Xu; Qiwen Yang
Journal:  Infect Drug Resist       Date:  2021-03-05       Impact factor: 4.003

3.  In vitro Bactericidal Activities of Combination Antibiotic Therapies Against Carbapenem-Resistant Klebsiella pneumoniae With Different Carbapenemases and Sequence Types.

Authors:  Jocelyn Qi-Min Teo; Nazira Fauzi; Jayden Jun-Yuan Ho; Si Hui Tan; Shannon Jing-Yi Lee; Tze Peng Lim; Yiying Cai; Hong Yi Chang; Nurhayati Mohamed Yusoff; James Heng-Chiak Sim; Thuan Tong Tan; Rick Twee-Hee Ong; Andrea Lay-Hoon Kwa
Journal:  Front Microbiol       Date:  2021-12-13       Impact factor: 5.640

4.  The in vitro activity of polymyxin B and tigecycline alone and combination with other antibiotics against carbapenem-resistant Enterobacter cloacae complex isolates, including high-risk clones.

Authors:  Yongxin Zhao; Chunjiang Li; Jisheng Zhang; Yanjun Fu; Kewang Hu; Shanshan Su; Yong Wang; Huiling Li; Xiaoli Zhang
Journal:  Ann Transl Med       Date:  2019-12

Review 5.  Losing the Battle but Winning the War: Can Defeated Antibacterials Form Alliances to Combat Drug-Resistant Pathogens?

Authors:  Song Oh; Raymond Chau; Anh T Nguyen; Justin R Lenhard
Journal:  Antibiotics (Basel)       Date:  2021-05-28

Review 6.  Antimicrobial Stewardship Programs: A Review of Strategies to Avoid Polymyxins and Carbapenems Misuse in Low Middle-Income Countries.

Authors:  Fabrício Rodrigues Torres de Carvalho; João Paulo Telles; Felipe Francisco Bodan Tuon; Roberto Rabello Filho; Pedro Caruso; Thiago Domingos Correa
Journal:  Antibiotics (Basel)       Date:  2022-03-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.